Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart, Marion Procter, Debora Fumagalli, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 13, pp. 1448-1457
Open Access | Times Cited: 290

Showing 1-25 of 290 citing articles:

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Harold J. Burstein, Giuseppe Curigliano, Beat Thürlimann, et al.
Annals of Oncology (2021) Vol. 32, Iss. 10, pp. 1216-1235
Open Access | Times Cited: 603
Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain, Mythili Shastry, Erika Hamilton
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 101-126
Open Access | Times Cited: 535
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Amanda Kerr, David Dodwell, Paul McGale, et al.
Cancer Treatment Reviews (2022) Vol. 105, pp. 102375-102375
Open Access | Times Cited: 196
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
Yutian Zou, Shaoquan Zheng, Xinhua Xie, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 157
Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning
Jialiang Yang, Jie Ju, Lei Guo, et al.
Computational and Structural Biotechnology Journal (2021) Vol. 20, pp. 333-342
Open Access | Times Cited: 152
Evolution of low HER2 expression between early and advanced-stage breast cancer
Paolo Tarantino, Sara Gandini, Eleonora Nicolò, et al.
European Journal of Cancer (2022) Vol. 163, pp. 35-43
Closed Access | Times Cited: 140
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose, et al.
Biochemical Pharmacology (2022) Vol. 204, pp. 115209-115209
Open Access | Times Cited: 85
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Elisa Agostinetto, Joseph Gligorov, Martine Piccart
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 763-774
Open Access | Times Cited: 82
Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jens Huober, Carlos H. Barrios, Naoki Niikura, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 25, pp. 2946-2956
Open Access | Times Cited: 79
Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
Pashtoon Murtaza Kasi, Gordon Fehringer, Hiroya Taniguchi, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 72
What Is Known about Breast Cancer in Young Women?
Jie Wei Zhu, Parsa Charkhchi, Shadia Adekunte, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1917-1917
Open Access | Times Cited: 58
Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
Laura López-González, Alicia Sánchez Cendra, Cristina Sánchez Cendra, et al.
Medicina (2024) Vol. 60, Iss. 1, pp. 168-168
Open Access | Times Cited: 17
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
Gail D. Lewis Phillips, Guangmin Li, Jun Guo, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
HER2-Positive Breast Cancer Treatment and Resistance
Jamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutiérrez, et al.
Advances in experimental medicine and biology (2025), pp. 495-525
Closed Access | Times Cited: 2
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
Yun Ling, Gehao Liang, Qun Lin, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 64
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
Ralf‐Dieter Hofheinz, Kirsten Merx, Georg Martin Haag, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 32, pp. 3750-3761
Closed Access | Times Cited: 59
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
Nadia Harbeck
The Breast (2022) Vol. 62, pp. S12-S16
Open Access | Times Cited: 53
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification
Jianbin Li, Zefei Jiang
Cancer Biology and Medicine (2022) Vol. 19, Iss. 6, pp. 1-5
Open Access | Times Cited: 51
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Guillermo Villacampa, Nadine Tung, Sònia Pernas, et al.
Annals of Oncology (2023) Vol. 34, Iss. 9, pp. 783-795
Open Access | Times Cited: 28
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
Francisco Ayala de la Peña, Silvia Antolín, Joaquín Gavilá Gregori, et al.
Clinical & Translational Oncology (2023) Vol. 25, Iss. 9, pp. 2647-2664
Open Access | Times Cited: 23
Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence
Kamel Debbi, N. Grellier, Gokoulakrichenane Loganadane, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2278-2278
Open Access | Times Cited: 22
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer
Hailin Zou, Juan Luo, Yibo Guo, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101051-101051
Open Access | Times Cited: 12
Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
Liang Huang, Da Pang, Hongjian Yang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer
Yuqin Peng, Xiang Zhang, Ya Qiu, et al.
American Journal of Roentgenology (2024) Vol. 222, Iss. 4
Closed Access | Times Cited: 11
Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options
Sarah Premji, Ciara C. O’Sullivan
Breast Cancer Basic and Clinical Research (2024) Vol. 18
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top